Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
March 2022
-
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
Les actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-… -
Media Release
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
Die Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien… -
Media Release
Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis
Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in…
February 2022
-
Media Release
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for… -
Key Release
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12… -
Key Release
Novartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative… -
Key Release
Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den…
January 2022
-
Media Release
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo,… -
Media Release
Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function
Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of… -
Media Release
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a…